AAAAAA
Results:
1-15
|
Results: 15
Authors:
ENZINGER PC
ILSON DH
SALTZ LB
OREILLY EM
KELSEN DP
Citation: Pc. Enzinger et al., IRINOTECAN AND CISPLATIN IN UPPER GASTROINTESTINAL MALIGNANCIES, Oncology, 12(8), 1998, pp. 110-113
Authors:
ILSON DH
AJANI J
BHALLA K
FORASTIERE A
HUANG Y
PATEL P
MARTIN L
DONEGAN J
PAZDUR R
REED C
KELSEN DP
Citation: Dh. Ilson et al., PHASE-II TRIAL OF PACLITAXEL, FLUOROURACIL, AND CISPLATIN IN PATIENTSWITH ADVANCED-CARCINOMA OF THE ESOPHAGUS, Journal of clinical oncology, 16(5), 1998, pp. 1826-1834
Authors:
SALTZ LB
SCHWARTZ GK
ILSON DH
QUAN V
KELSEN DP
Citation: Lb. Saltz et al., A PHASE-II STUDY OF TOPOTECAN ADMINISTERED 5 TIMES DAILY IN PATIENTS WITH ADVANCED GASTRIC-CANCER, American journal of clinical oncology, 20(6), 1997, pp. 621-625
Authors:
AJANI JA
ILSON DH
KELSEN DP
Citation: Ja. Ajani et al., PACLITAXEL IN THE TREATMENT OF PATIENTS WITH UPPER GASTROINTESTINAL CARCINOMAS, Seminars in oncology, 23(5), 1996, pp. 55-58
Authors:
AJANI JA
ILSON DH
KELSEN DP
Citation: Ja. Ajani et al., THE ACTIVITY OF PACLITAXEL IN GASTROINTESTINAL TUMORS, Seminars in oncology, 22(5), 1995, pp. 46-50
Authors:
AJANI JA
ILSON DH
DAUGHERTY K
KELSEN DP
Citation: Ja. Ajani et al., PACLITAXEL IN THE TREATMENT OF CARCINOMA OF THE ESOPHAGUS, Seminars in oncology, 22(3), 1995, pp. 35-40
Authors:
KELSEN DP
ILSON DH
Citation: Dp. Kelsen et Dh. Ilson, CHEMOTHERAPY AND COMBINED-MODALITY THERAPY FOR ESOPHAGEAL CANCER, Chest, 107(6), 1995, pp. 224-232
Authors:
ILSON DH
SIROTT M
SALTZ L
HEELAN R
HUANG Y
KERESZTES R
KELSEN DP
Citation: Dh. Ilson et al., A PHASE-II TRIAL OF INTERFERON-ALPHA 2A, 5-FLUOROURACIL, AND CISPLATIN IN PATIENTS WITH ADVANCED ESOPHAGEAL-CARCINOMA, Cancer, 75(9), 1995, pp. 2197-2202
Authors:
BOSL GJ
ILSON DH
RODRIGUEZ E
MOTZER RJ
REUTER VE
CHAGANTI RSK
Citation: Gj. Bosl et al., CLINICAL RELEVANCE OF THE I(12P) MARKER CHROMOSOME IN GERM-CELL TUMORS, Journal of the National Cancer Institute, 86(5), 1994, pp. 349-355
Authors:
AJANI JA
ILSON DH
DAUGHERTY K
PAZDUR R
LYNCH PM
KELSEN DP
Citation: Ja. Ajani et al., ACTIVITY OF TAXOL IN PATIENTS WITH SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF THE ESOPHAGUS, Journal of the National Cancer Institute, 86(14), 1994, pp. 1086-1091
Authors:
AJANI JA
DODD LG
DAUGHERTY K
WARKENTIN D
ILSON DH
Citation: Ja. Ajani et al., TAXOL-INDUCED SOFT-TISSUE INJURY SECONDARY TO EXTRAVASATION - CHARACTERIZATION BY HISTOPATHOLOGY AND CLINICAL COURSE, Journal of the National Cancer Institute, 86(1), 1994, pp. 51-53
Authors:
LAW TM
ILSON DH
MOTZER RJ
Citation: Tm. Law et al., PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Investigational new drugs, 12(2), 1994, pp. 143-145
Authors:
ILSON DH
KELSEN DP
Citation: Dh. Ilson et Dp. Kelsen, COMBINED-MODALITY THERAPY IN THE TREATMENT OF ESOPHAGEAL CANCER, Seminars in oncology, 21(4), 1994, pp. 493-507
Authors:
ILSON DH
KELSON DP
Citation: Dh. Ilson et Dp. Kelson, CHEMOTHERAPY IN ESOPHAGEAL CANCER, Anti-cancer drugs, 4(3), 1993, pp. 287-299
Authors:
ILSON DH
MOTZER RJ
RODRIGUEZ E
CHAGANTI RSK
BOSL GJ
Citation: Dh. Ilson et al., GENETIC-ANALYSIS IN THE DIAGNOSIS OF NEOPLASMS OF UNKNOWN PRIMARY TUMOR SITE, Seminars in oncology, 20(3), 1993, pp. 229-237
Risultati:
1-15
|